Saverio Minucci

Saverio Minucci

Auto-generated profile, based on publicly available information

Saverio Minucci

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cancer Cell
Verified
Journal Article
Closed access
Mohamed ElgendyMohamed Elgendy
Mohamed Elgendy
MCMarco Cirò
Marco Cirò
AHAmir Hosseini
Amir Hosseini
JWJakob Weiszmann
Jakob Weiszmann
Luca MazzarellaLuca Mazzarella
Luca Mazzarella
SMSaverio Minucci
Saverio Minucci

23 February 2016 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ECElena Ceccacci
Elena Ceccacci
SMSaverio Minucci
Saverio Minucci
Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.

12 July 2017 in Epigenomics
Verified
Journal Article
Closed access
AHAmir Hosseini
Amir Hosseini
SMSaverio Minucci
Saverio Minucci
Histone methylation plays a key role in the regulation of chromatin structure, and its dynamics regulates important cellular processes. The investigation of the role of alterations in histone methylation in cancer has led to the identification of histone methyltransferases and demethylases as promising novel targets for therapy. Lysine-specific demethylase 1(LSD1, also known as KDM1A) is the first discovered histone lysine demethylase, with the ability to demethylase H3K4me1/2 and H3K9me1/2 at target loci in a context-dependent manner. LSD1 regulates the balance between self-renewal and differentiation of stem cells, and is highly expressed in various cancers, playing an important role in differentiation and self-renewal of tumor cells. In this review, we summarize recent studies about the LSD1, its role in normal and tumor cells, and the potential use of small molecule LSD1 inhibitors in therapy.

23 January 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LMLuca Magnani
Luca Magnani
GFGianmaria Frige
Gianmaria Frige
RGRaffaella Maria Gadaleta
Raffaella Maria Gadaleta
GCGiacomo Corleone
Giacomo Corleone
SFSonia Fabris
Sonia Fabris
SMSaverio Minucci
Saverio Minucci
Saverio Minucci, Giancarlo Pruneri, Luca Magnani and colleagues identify acquired CYP19A1 amplification as a mechanism of resistance to aromatase inhibitors in ERα metastatic breast cancer. Mechanistically, they show that CYP19A1 amplification results in increased aromatase activity and estrogen-independent ERα binding to target genes. Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, patients with estrogen receptor (ERα)-positive breast cancer are treated with adjuvant endocrine therapy2, including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs)3. However, more than 20% of patients relapse within 10 years and eventually progress to incurable metastatic disease4. Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases. We found that 21.5% of AI-treated, relapsed patients had acquired CYP19A1 (encoding aromatase) amplification (CYP19A1amp). Relapsed patients also developed numerous mutations targeting key breast cancer–associated genes, including ESR1 and CYP19A1. Notably, CYP19A1amp cells also emerged in vitro, but only in AI-resistant models. CYP19A1 amplification caused increased aromatase activity and estrogen-independent ERα binding to target genes, resulting in CYP19A1amp cells showing decreased sensitivity to AI treatment. These data suggest that AI treatment itself selects for acquired CYP19A1amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients.

10 April 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
RRRoberto Ravasio
Roberto Ravasio
ECElena Ceccacci
Elena Ceccacci
LNLuciano Nicosia
Luciano Nicosia
AHAmir Hosseini
Amir Hosseini
PRPier Luigi Rossi
Pier Luigi Rossi
SMSaverio Minucci
Saverio Minucci
The study addresses the mechanism through which inhibition of LSD1 sensitizes AML cells to retinoic acid–induced differentiation.

28 November 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Mohamed ElgendyMohamed Elgendy
Mohamed Elgendy
Amal Kamal Abdel-AzizAmal Kamal Abdel-Aziz
Amal Kamal Abdel-Aziz
SRSalvatore Lorenzo Renne
Salvatore Lorenzo Renne
VBViviana Bornaghi
Viviana Bornaghi
GPGiuseppe Procopio
Giuseppe Procopio
SMSaverio Minucci
Saverio Minucci
Most patients who initially respond to treatment with the multi–tyrosine kinase inhibitor sunitinib eventually relapse. Therefore, developing a deeper understanding of the contribution of sunitinib’s numerous targets to the clinical response or to resistance is crucial. Here, we have shown that cancer cells respond to clinically relevant doses of sunitinib by enhancing the stability of the antiapoptotic protein MCL-1 and inducing mTORC1 signaling, thus evoking little cytotoxicity. Inhibition of MCL-1 or mTORC1 signaling sensitized cells to clinically relevant doses of sunitinib in vitro and was synergistic with sunitinib in impairing tumor growth in vivo, indicating that these responses are triggered as prosurvival mechanisms that enable cells to tolerate the cytotoxic effects of sunitinib. Furthermore, higher doses of sunitinib were cytotoxic, triggered a decline in MCL-1 levels, and inhibited mTORC1 signaling. Mechanistically, we determined that sunitinib modulates MCL-1 stability by affecting its proteasomal degradation. Dual modulation of MCL-1 stability at different dose ranges of sunitinib was due to differential effects on ERK and GSK3β activity, and the latter also accounted for dual modulation of mTORC1 activity. Finally, comparison of patient samples prior to and following sunitinib treatment suggested that increases in MCL-1 levels and mTORC1 activity correlate with resistance to sunitinib in patients.